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Role and expression of FRS2 and FRS3 in prostate
cancer
Tania Valencia1, Ajay Joseph1, Naveen Kachroo1, Steve Darby2, Susan Meakin3 and Vincent J Gnanapragasam1*
Abstract
Background: FGF receptor substrates (FRS2 and FRS3) are key adaptor proteins that mediate FGF-FGFR signalling
in benign as well as malignant tissue. Here we investigated FRS2 and FRS3 as a means of disrupting global FGF
signalling in prostate cancer.
Methods: FRS2 and FRS3 manipulation was investigated in vitro using over-expression, knockdown and functional
assays. FRS2 and FRS3 expression was profiled in cell lines and clinical tumors of different grades.
Results: In a panel of cell lines we observed ubiquitous FRS2 and FRS3 transcript and protein expression in both
benign and malignant cells. We next tested functional redundancy of FRS2 and FRS3 in prostate cancer cells. In
DU145 cells, specific FRS2 suppression inhibited FGF induced signalling. This effect was not apparent in cells stably
over-expressing FRS3. Indeed FRS3 over-expression resulted in enhanced proliferation (p = 0.005) compared to
control cells. Given this functional redundancy, we tested the therapeutic principle of dual targeting of FRS2 and
FRS3 in prostate cancer. Co-suppression of FRS2 and FRS3 significantly inhibited ERK activation with a concomitant
reduction in cell proliferation (p < 0.05), migration and invasion (p < 0.05). Synchronous knockdown of FRS2 and
FRS3 with exposure to cytotoxic irradiation resulted in a significant reduction in prostate cancer cell survival
compared to irradiation alone (p < 0.05). Importantly, this synergistic effect was not observed in benign cells.
Finally, we investigated expression of FRS2 and FRS3 transcript in a cohort of micro-dissected tumors of different
grades as well as by immunohistochemistry in clinical biopsies. Here, we did not observe any difference in
expression between benign and malignant biopsies.
Conclusions: These results suggest functional overlap of FRS2 and FRS3 in mediating mitogenic FGF signalling in
the prostate. FRS2 and FRS3 are not over-expressed in tumours but targeted dual inhibition may selectively
adversely affect malignant but not benign prostate cells.
Keywords: Prostate cancer, FGF signalling, FRS2, FRS3, Adaptor proteins
Background
The Fibroblast Growth Factor (FGF) pathway is an
important stimulus to cancer development and progres-
sion in many epithelial tumours [1-3]. In prostate cancer
many FGF ligands and FGF receptors (FGFR) have been
shown to be significantly over-expressed [4-8]. Targeted
inhibition of FGF signalling has shown promise in in
vitro studies but has so far not translated into clinically
useful therapies. A key problem is the inherent func-
tional redundancy in a system that has 23 known
ligands and 4 receptors [1,2]. All FGFs however require
the FGF receptor substrate (FRS) 2 and 3 adaptor pro-
teins to initiate down-stream signalling [9]. These pro-
teins act as coning centres and are crucial for
recruitment and activation of the MAPK and other sig-
nalling cascades following phosphorylation of FGFRs.
FRS2 and FRS3 share 49% sequence identity and contain
a N-terminal myristylation domain important for mem-
brane anchoring, a phospho-tyrosine binding (PTB)
domain through which they interact with FGFRs and a C-
terminal domain with tyrosine phosphorylation sites for
Grb2 and phosphatase Shp2 [9]. The FRS2-Grb2-Sos and
FRS2-Grb2-Gab1 complexes activate the RAS/MAPK
pathway and the PI3 kinase pathway, respectively [10].
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FRS2 not only binds to FGFRs, but also to the TrkA,
VEGF and RET receptors suggesting a broad role in signal
transduction [11,12]. FRS2 plays an important role in cell
differentiation, proliferation, migration and cycle arrest
[13-16]. FRS2 null mouse die at E7.0-E7.5 due to impair-
ment in development [17]. The function of FRS3 is less
well understood and FRS3 null mice have not been
reported. Ectopic expression of FRS3 in fibroblast derived
from FRS2 -/-mouse embryos however has been shown to
rescue FGF induced ERK activation suggesting functional
overlap in embryogenesis [18]. FRS3 has been proposed to
have an important role in negative regulation of EGF
receptor signalling [19,20] and recently has been reported
as a novel microtubule-associated protein [21].
FRS sits at the critical juncture between the FGFR and
downstream signal transduction. It is therefore a poten-
tially attractive target to disrupt the mitogenic and
tumourigenic effects of multiple FGFs. An important
first step however is to determine the relative expression
and function of FRS2 and FRS3 in a specific cancer.
There have been very few studies of FRS2 and FRS3 in
clinical cancers and no reports in prostate cancer. In
lung cancer, reduced FRS3 was associated with a poor
clinical prognosis [19]. Conversely, in thyroid cancers
FRS3 expression was unchanged but FRS2 expression
was increased [22] suggesting potential tissue specific
FRS2 and FRS3 changes in tumours. In this study we
investigated the relative expression and functional role
of FRS2 and FRS3 in prostate cancer.
Methods
Cell lines and stable construct
Malignant and benign prostate cell lines were cultured in
RPMI (Invitrogen) supplemented with 10% FBS. All cell
lines used (LNCaP/DU145/PC3/PNT1A/PNT2) were pur-
chased commercially (American Type Culture Collection
or Health Protection Agency Culture Collections). 2 μg of
myc-tag pCDNA3.1-FRS3 (received from Dr S Meakin) or
pcDNA3.1 empty was transfected using Lipofectamine
2000 (Invitrogen). Transfected cells were placed under
G418-sulphate selection for 14-20 days. Individual colo-
nies were removed by trypsinization and expanded, and
clones screened for FRS3 expression. For androgen induc-
tion experiments, LNCaP cells were initially grown for 24
hours in standard media and then maintained in charcoal
stripped serum supplemented media for 24 hours. Follow-
ing this, synthetic androgen (R1881) was added at a dose
of 10 nM. Cells were harvested at the indicated time
points and RNA extracted for real time PCR analysis of
FRS2 and FRS3 and PSA expression.
siRNA and Real time polymerase chain reaction
Cells were grown for 24 hours prior to transfection. 33
nM of siRNA oligonucleotides: Silencer(R) Select Pre-
designed siRNA FRS2, s21262 (Applied Biosystems) and
ON-TARGETplus FRS3, L-019038-00-0020 (Dharma-
con) was used to transfect cells. Silencer(R) Select Nega-
tive Control #1 siRNA, 4390844 (Applied Biosystems)
was used in parallel as the scramble control. The results
presented are the mean value of six separate set of
experiments. Total RNA was extracted using RNeasy
Mini Kit (Qiagen) and reverse transcribed using Tran-
scriptor cDNA Synthesis Kit (Roche Diagnostics)
according to the manufacturer’s instructions. Real time
sequence specific Taqman PCR primers for human
FRS2 (Hs00183614_m1), FRS3 (Hs00183610_m1) and
GAPDH (Hs02786624_g1) were purchased from Applied
Biosystems. qPCR was preformed with Light Cycler 480
(Roche Diagnostics) and Taqman Universal PCR Master
Mix (Applied Biosystems) and corrected for GAPDH
expression. PCR was repeated in triplicate and per-
formed three times with results expressed as the mean
and standard deviations.
Cell proliferation assays
Cells were seeded at a density of 3000 (DU145, DUEV,
DUFRS3) and 5000 (PC3, PNT2) cells in 96-well plates
and allowed to grow for 36 h. Medium lacking serum
was termed ‘basal medium’ (BM), while medium con-
taining 10% FBS was termed as “full medium” (FM).
Cells were then starved in BM for 16 h before stimula-
tion with FM. Cell proliferation was assessed with WST-
1 reagent (Roche Diagnostics). Experiments were
repeated in triplicate and done three times.
Western blotting
Cells were lysed in Laemmli buffer and denatured. Sam-
ples were then separated using 10% Bis-Tris pre-cast
gels (Invitrogen), followed by transfer to a PDVF mem-
brane (GE Healthcare). Primary antibodies: FRS2-A5
(sc-17841), pERK-E4 (sc-7383), ERK-6G11 (sc-81458), c-
Myc-9E10 (sc-40) were purchased from Santa Cruz Bio-
technologies, Abcam (a-tubulin, ab4074-100) and BD
Biosciences (PARP, 65196E). FRS3 antibody was
received from Dr S Meakin and has been previously
described [22]. Primary antibody complexes were
detected using HRP-conjugated secondary antibodies
(Dako). Protein bands were visualised using ECL (GE
Healthcare).
Migration and invasion assays
Transfected cells were re-plated out into BD migration
or invasion chambers (Scientific Laboratory Supplies) in
basal medium (BM) at a concentration of 80, 000 cells
per insert. FM or FGF1 (10 ng ml-1), FGF2 (10 ng ml-1)
and FGF8 (10 ng ml-1) prepared in basal media were
used in the lower chamber as chemoattractant. Cells
were allowed to migrate or invade for 24 hours and
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fixed in methanol for 20 minutes at -20°C, stained with
haematoxylin, washed with dH2O and allowed to dry
before mounting them in a microscopic slide with DPX
(Sigma Aldrich). Cells were counted using a bright field
microscope at 20× magnification. Five different fields of
view were used to obtain an average count per section.
Results shown are the mean of three experiments and
expressed as a fold increase over un-induced scramble
controls (migration) or as invasion index (compared to
and corrected for control inserts). Statistical analysis was
performed using two-tailed Student’s T-test. p < 0.05
being significant.
Radiation survival assays
Cells were down-regulated for FRS2 and FRS3 expres-
sion by siRNA as described and re-plated at 1000 cells
per well in 6-well plates and left to grow for 24 h. Cells
were then subjected to different doses of radiation (1 Gy
and 3 Gy) in situ and left for 10 days. At the end of this
period dead cells were washed off and residual colonies
were Giemmsa stained and counted. Counts were taken
in four separate areas and averaged for each plate.
Experiments were repeated in triplicate and done three
times. Results are expressed as a percentage compared
to non-irradiated cells.
Clinical biopsy laser micro-dissection and sample
preparation
Diagnostic prostate biopsies from men with histological
proven prostate cancer were identified from a pathology
resource and used in accordance with ethical approval
gained from Cambridgeshire local ethics committee in
2009 (Ref: 09/H0308/42). All samples were anonymised
at source. As all samples were archival, collected surplus
to diagnostic need and anonymous at the point of col-
lection no specific patient consent was deemed neces-
sary by the ethics board for use of these samples.
Formalin fixed paraffin embedded tissue (FFPE) excess
to diagnostic need were sectioned at 10 μm thickness
onto Polyethylene napthalate (PEN) membrane slides
(Leica TM). Slides were deparaffinised twice with xylene,
rehydrated using graduated ethanol/DEPC water then
H&E stained. Slides were pre-marked for benign or
malignant areas and by Gleason grade (Grades 3/4/5)
using the diagnostic matching slide as a guide. Pre-
marked slides were then micro-dissected using a Leica
TM LMD6000 system. Micro-dissected tissue was then
subjected to RNA extraction using the High Pure RNA
Paraffin Kit (Roche Diagnostics). cDNA was synthesised
from the isolated RNA using the Transcriptor High
Fidelity cDNA synthesis kit (Roche Diagnostics). Pre-
amplification was carried out using manufacturer’s
recommendation (Applied Biosystems) with Taqman
PreAmp master mix. PCR was carried out using primers
as described below. All samples were first quality
checked by expression profiling of at least three house-
keeping genes (RPL13, GAPDH, b actin) before being
used for expression analysis of FRS2 and FRS3 in this
study. Statistical comparison was made using the Krus-
kal Wallis test. p < 0.05 was taken as being significant.
Immunohistochemistry
The tissue microarray (TMA) used in this study has
been described [5]. The study cohort included 129 can-
cers and 36 benign biopsies. All material was used in
accordance with approval granted by the local hospital
ethical committee. Mouse monoclonal FRS2, (Santa
Cruz) and rabbit polyclonal FRS3 antibody (received
from Dr S Meakin) used in this study, have been pre-
viously validated for use in immunohistochemistry
[18,22]. Scoring was done by two independent observers
blinded to the clinical detail and the scores collated and
analysed by a third investigator (VJG). The score was
carried out by assessing the intensity of stain for each
core, where immunoreactivity signals was assessed as
being absent or weak (0/+) and moderate or strong (+
+/+++). Data were analysed using the Kruskal-Wallis
test. p < 0.05 was taken as being statistically significant.
Results
Functional redundancy of FRS2 and FRS3 in prostate
cancer cells
A panel of cell lines was first analysed by real time PCR
to define expression levels in prostate cells. FRS2 and
FRS3 mRNA were ubiquitously expressed in normal
epithelial prostate cell lines (PNT1A/PNT2) and pros-
tate cancer cell lines (LNCaP, DU145 and PC3) (Figure
1A). FRS2 levels were generally higher in all cell lines
compared to FRS3 regardless of androgen receptor
expression status. A similar pattern of expression in
these cell lines was seen in western analysis of FRS2 and
FRS3 protein (Figure 1A). We also tested if FRS expres-
sion was inducible by androgens. In LNCaP cells neither
FRS2 nor FRS3 mRNA expression levels were increased
by the addition of androgens suggesting that they are
not androgen regulated (Figure 1B). In contrast, simulta-
neous analysis of PSA expression as a control was signif-
icantly increased in LNCaP cells treated with androgens.
The function of FRS2 has been well explored in the lit-
erature but less is known about FRS3. Given evidence of
expression overlap in our cell lines, we tested functional
overlap between FRS2 and FRS3 in prostate cancer. A
stable myc-tag FRS3 over-expressing clone in DU145
prostate cancer cell lines was first generated (DUFRS3)
(Figure 2A). DU145 were selected as an androgen inde-
pendent cell line with relatively low FRS3 expression
compared to FRS2 (Figure 1A). In proliferation assays
FRS3 over-expression significantly enhanced cell
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proliferation in response to stimulation by FGF1 (p <
0.005), FGF2 (p < 0.001) and FGF8 (p < 0.001) com-
pared to empty vector control (Figure 2B). FRS3 has
previously been implicated as an inhibitor of EGF sig-
nalling [19,20]. In these experiments however increasing
FRS3 did not appear to alter (increase or inhibit) the
magnitude of EGF stimulated proliferation (Figure 2B).
We next asked if FRS3 over-expression could compen-
sate for FRS2 down-regulation as has been previously
described in embryogenesis [18]. In serum-starved
DUEV cells, the addition of FGFs resulted in enhanced
proliferation (p < 0.005) (Figure 2C) concomitant with
rapid phosphorylation of ERK (Figure 2D, upper panels).
Targeted FRS2 knock down reduced this induction
regardless of the FGF ligand used (Figure 2C, D upper
panels). The effect of silencing FRS2 in the DUFRS3
clone was next tested. Here, over-expression of FRS3
was able to compensate for the effect of targeted knock
down of FRS2 when stimulated with different FGFs (Fig-
ure 2C). In parallel studies, FRS2 knock down in FRS3
over-expression clones had no discernable effect on ERK
phosphorylation (Figure 2D, lower panels). These studies
suggest functional redundancy between FRS2 and FRS3
in prostate cancer cells.
Effect of dual silencing of FRS2 and FRS3
Our results suggest that both FRS2 and FRS3 are impor-
tant in FGF mediated signalling in prostate cancer. We
therefore investigated the effect of dual targeting of
FRS2 and FRS3. The efficiency of dual silencing was
confirmed at the protein level. Full media stimulation of
scramble transfected DU145 and PC3 cells resulted in a
significant increase in proliferation compared to un-sti-
mulated cells. Dual silencing of FRS2 and FRS3 in PC3
and DU145 however reduced this induction in compari-
son to these scramble controls (p < 0.005) (Figure 3A
and 3B). We did observe that the dual knock down
effect was more noticeable in PC3 cells compared to
DU145 particularly in the earlier phases of proliferation.
This effect could be due to differences in transfection
efficiency between the cell lines and/or inherent variabil-
ity between the cell types in response to FGF stimula-
tion and FRS utilisation. Immunoblot analysis did
demonstrate comparable down-regulation of FRS2 and
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Figure 1 FRS2 and FRS3 mRNA expression in prostate cell lines. A: FRS2 and FRS3 mRNA expression in benign and malignant cell lines as
well as protein expression by western blot using FRS2 and FRS3 specific antibodies. B: FRS2 and FRS3 and PSA (positive control) expression in
LNCaP cells treated with androgens and assayed at different time points.
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Figure 2 Mitogenic effect of FRS3 over-expression and functional redundancy. A: Immunoblot analysis showing FRS3-Myc protein over-
expression in DU145 cell line compared to empty vector control cell line following stable transfection with FRS3. B: FRS3 over-expression
enhances cell proliferation in DU145 in response to full media and different FGFs. C: FRS2 knock down is compensated for by FRS3 over-
expression in proliferation assay in response to different FGF stimulation. Inset image shows immunoblot representative of FRS2 down-regulation
following siRNA transfection in DU145 cells. D: FRS3 over-expression reverses the inhibitory effect of FRS2 suppression by siRNA on pERK
activation. *p < 0.005.
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Figure 3 Effect of dual targeting of FRS2 and FRS3 in cancer and benign cells. A: Immunoblot analysis showing representative dual down-
regulation of FRS2 and FRS3 protein in PC3 cell line and corresponding proliferation assay stimulated with full media. B: Down-regulation of
FRS2 and FRS3 in DU145 cell line and corresponding proliferation assay stimulated with full media. C: Down-regulation of FRS2 and FRS3 in
benign PNT2 cell line and corresponding proliferation assay stimulated with full media. *p < 0.005. siFRS2/3- siRNA against FRS2 and FRS3
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FRS3 protein in both cell lines following transfection.
We next repeated the experiments in PNT2 benign
prostate cells known to respond to FGF stimulation. In
these cells we surprisingly observed that FRS2 and FRS3
suppression did not alter cell proliferation (Figure 3C).
We next tested the effect of dual FRS2 and FRS3 silen-
cing in the context of different FGF stimulation in
migration and invasion experiments. Treatment of PC3
scramble control cells with FGF1, FGF2 and FGF8
resulted in a significant increase in migration compared
to un-stimulated controls. FRS2 and FRS3 dual knock
down in these cells however significantly reduced migra-
tion regardless of the ligand used in comparison to
scramble transfected controls (Figure 4A). Similar
results were seen in experiments with DU145 cells (Fig-
ure 4B). Invasion assays were next carried out in PC3
cells using FGFs as well as EGF as a chemo-attractant.
Dual silencing of FRS2 and FRS3 in PC3 cells reduced
the ability of cells to induce invasion upon FGF stimula-
tion (p < 0.005) (Figure 4C). No significant change in
the invasion index was noted when siRNA FRS2 and
FRS3 PC3 cells were stimulated with EGF compared to
EGF-stimulated scramble control cells. A similar finding
was observed for siRNA FRS2 and FRS3 transfected
DU145 cells in invasion studies (Figure 4D) (p < 0.05).
The effect of dual knock down of FRS2 and FRS3 on
FGF induced MAPK activation was next tested. In this
experiment, the intensity and duration of ERK phos-
phorylation following PC3 cell stimulation with either
FGF1 or FGF2 in siRNA treated FRS2 and FRS3 cells
was dramatically reduced compared to scramble con-
trols in keeping with the functional data observed above
(Figure 4E).
Dual silencing of FRS2 and FRS3 reduces cell recovery
after exposure to radiation
We have observed that combined silencing of FRS2 and
FRS3 resulted in a significant inhibition in FGF induced
ERK activation in prostate cancer cell lines. MAPK sig-
nalling has been shown to play a major role in the can-
cer cell response and recovery to radiation therapy
[23,24]. We therefore tested if targeting FRS2 and FRS3
was a potential therapeutic target in combination with
radiation. In these studies silencing FRS2 and FRS3 in
PC3 cells significantly inhibited colony formation follow-
ing irradiation compared to scramble transfected con-
trols (p < 0.05) (Figure 5A). A similar finding was
observed in siRNA FRS2 and FRS3 transfected DU145
cells (p < 0.002) (Figure 5B). These experiments were
next repeated with benign PNT2 cells. In contrast to
cancer cells, the clonogenic survival after radiation
between scramble and siRNA FRS2 and FRS3 cells was
not significantly different in these benign epithelial cell
lines (Figure 5C). We next tested whether manipulation
of FRS2 and FRS3 might have had a direct effect on
inducing cell apoptosis. siRNA FRS2 and FRS3 or
scramble transfected PC3 cells were assayed by immu-
noblotting for the extent of PARP cleavage following
irradiation (Figure 5D). In this experiment we did not
observe any difference in the levels of PARP cleavage in
either scramble or siRNA FRS2 and FRS3 transfected
samples. These results suggest that FRS2 and FRS3 sup-
pression is not likely to have a direct effect in enhancing
apoptosis. Rather, it is more likely that FRS2 and FRS3
suppression may function to inhibit pro-survival signal-
ling which can enhance cell recovery and proliferation
in the immediate period after a cytotoxic insult.
Expression analysis of FRS2 and FRS3 in prostate cancer
An important therapeutic question is if either FRS2 or
FRS3 are over-expressed in cancer. We therefore tested
expression of FRS2 and FRS3 transcript by quantitative
real time PCR in a panel of archival clinical prostate
cancers using methods previously developed in our
group [25]. Benign (n = 5), Grade 3 (n = 4), Grade 4 (n
= 6) and Grade 5 (n = 9) tumors each derived from
separate individual patients were micro-dissected and
RNA extracted and profiled for FRS2 and 3 mRNA
expression. In this analysis we found that overall FRS2
transcript levels were higher in benign and malignant
biopsies compared to FRS3 consistent with our findings
in cell lines (Figure 6A). There was however no differ-
ence in expression of FRS2 or FRS3 comparing benign
or malignant samples (p = 0.8 for both comparisons).
We also tested if with increasing cancer grades there
was any evidence of a progressive increase or decrease
in expression and found no significant alterations (p =
0.23 for FRS2 and p = 0.87 for FRS3). To further inves-
tigate expression in clinical tissue, we interrogated a
publicly available dataset. The MSKCC Prostate Onco-
genome Project was interrogated for FRS2 and FRS3
transcript expression (n = 131 primary tumours with
mRNA data available) using the cBio Cancer Genomics
Portal [26]. In this resource (using a Z threshold value
of 2.0) there was minimal alteration in FRS2 or FRS3
expression. Only 6% and 8% of tumours had any
changes in FRS2 and FRS3 expression compared to nor-
mal controls respectively (Figure 6B). These findings
corroborate our own data from clinical samples and
show that both FRS2 and FRS3 mRNA are expressed in
clinical samples suggesting expression redundancy. FRS2
appears to be the predominantly expressed transcript in
prostate tissue but neither is significantly over-expressed
or down-regulated in the transition to a malignant phe-
notype. Finally, we next asked if these observations were
also true in terms of protein expression. Using a clinical
prostate tissue microarray we tested for expression of
FRS3 and FRS3 in cohorts of defined cohorts of benign
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Figure 4 Dual targeting of FRS2 and FRS3 is a global inhibitor of FGF induction. A and B: Migration experiments in PC3 and DU145
stimulated with different FGFs. C and D: Invasion assays for PC3 and DU145 cancer prostate cell lines in the presence of different FGFS and
EGF. E: Silencing FRS2 and FRS3 inhibits FGF-simulated ERK activation of PC3 cells by FGF1 and FGF2 (*p < 0.005). siFRS2/3- siRNA against FRS2
and FRS3
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(n = 34) and malignant (n = 129) prostate samples (Fig-
ure 7). Comparison of overall expression in these two
groups demonstrated no overall significant difference
between the groups at the protein level for either FRS2
or FRS3.
Discussion
Dysregulation of FGF signalling is a common event in
many types of cancers. In prostate cancer, FGFR1 and
FGFR4 as well as the ligands FGF-1, FGF-2, FGF-6,
FGF-8, FGF-9, and FGF-17 are all known to be over-
**
* *
*
C D
Scramble
SiFRS2/3
Scramble
SiFRS2/3
A B
Scramble
SiFRS2/3
*
Figure 5 Dual targeting of FRS2/FRS3 as an adjunct to radiotherapy. A and B: Percentage change in the number of colony forming units
in PC3 and DU145 prostate cancer cell lines. C: Percentage change in the number of colony forming units in PNT2 prostate cell lines. (* <0.005;
**p <0.05). D: Effect of altering FRS2 and FRS3 levels on PARP cleavage in PC3 cells. siFRS2/3- siRNA against FRS2 and FRS3
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expressed [4,27-31]. The targeting of a common focal
point of FGF signalling such as FRS2 and FRS3 to dis-
rupt these diverse components is therefore highly
desirable. FRS2 is known to be involved in the activa-
tion of MAPK and PI3K signalling, cell proliferation,
migration and survival [9,17]. Much less is known
about FRS3 and in particular, its function in cancer
cells. In prostate cancer cells we observed that FRS3
over-expression was able to induce an enhanced mito-
genic phenotype in the presence of FGF stimulation.
More importantly, increased FRS3 was able to abrogate
the inhibitory effect of forced down-regulation of
FRS2. This implies FRS functional redundancy in
prostate cancer cells and a potentially important role
for FRS3 in maintaining aberrant FGF signalling. Such
functional redundancy has not previously been
reported in human tumours but is consistent with the
findings of Gotoh et al whereby weak activation of
MAPK by FGF stimulation in FRS2-/- mouse embryo-
nic fibroblast was reversed following ectopic over-
expression of FRS3 [18]. FRS2 and FRS3 are attractive
targets for manipulation because of their key central
role in FGF signalling. An important aim of this study
was to test the principle of manipulating FRS. Our
results had shown functional redundancy between
FRS2 and FRS3 hence siRNA against both FRS were
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Figure 6 Expression of FRS2 and FRS3 mRNA in clinical prostate cancer. A: Relative FRS2 and FRS3 mRNA expression in micro-dissected
benign and tumours of different Gleason grades. Each profile represents a tumour derived from an individual patient. B. Relative alterations in
FRS2 and FRS3 expression between benign and malignant prostate samples profiled in the MSKCC Prostate Oncogenome dataset (n = 131
tumours) (26). Here only a small minority of tumours had altered FRS2 and FRS3 mRNA with similar numbers exhibiting up-regulation or down-
regulation of each.
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used. Silencing FRS2 and FRS3 had a profound effect
on FGF induced proliferation, migration and invasion
regardless of the FGF ligand used and in two different
cancer cell lines. We did observe some differences in
the response of PC3 and DU145 cells to FRS2 and
FRS3 suppression. PC3 cells in particular responded
better to FGF stimulation and were also more affected
by induced FRS down-regulation compared to DU145
cells. Given apparently similar knock-down efficiency
from immunoblot assays, it is likely that this difference
is due to variability between the cell types in response
to FGF stimulation and pathway manipulation. FRS2
and FRS3 suppression in contrast, did not have any
appreciable effect on EGF stimulation in either of our
prostate cancer cell models. In contrast to this, FRS3
has been reported to inhibit EGF induced-transforma-
tion in Saos-2 cells and proliferation in NIH3T3 cells.
Suppression has been further reported to enhance the
effects of EGF signalling [19,20]. This discrepancy is
most likely due to differences in the cell and tumour
type studied.
In prostate cancer cell lines and a small cohort of
microdissected clinical tumours we failed to find any
association between altered FRS2 and FRS3 and the
transition to a malignant phenotype. In a larger protein
tissue microarray we also did not find any significant
association between overall expression and a benign and
malignant phenotype. FRS2 and FRS3 therefore do not
appear to be altered in prostate cancer. Work in other
tumour models have conversely shown differences in
FRS2 and FRS3 between benign and cancers with speci-
fic down-regulation of FRS3 or FR2 over-expression
[19,20,22]. The reason for differences in this pattern is
not clear but may represent cell and tumour specific dif-
ferential utilisation of the FRS proteins. Despite the lack
of over-expression we did observe that FRS2 and FRS3
A B
C
6366Cancer   (n=129)                                                
p=0.05
2410Benign    (n= 34)                                               
++/+++-/+
p valueFRS2 protein
X400 X400
X400
X400X100
X100
D
E F
6168Cancer   (n=129)                                                
p=0.44
1321Benign    (n= 34)                                               
++/+++-/+
p valueFRS3 protein
G
H
Figure 7 FRS2 and FRS3 protein expression in clinical prostate tissue. A and B: FRS2 and 3 expression respectively in benign prostate
glands C and D: FRS2 expression in malignant prostate biopsies. E and F: FRS3 expression in malignant prostate biopsies. G: Data table on FRS2
protein expression in human prostate tissue stratified by benign or cancer biopsies. H: Data table on FRS3 protein expression in human prostate
tissue stratified by benign or cancer biopsies.
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suppression had a significant and specific inhibitory
effect in cancer cell lines whereas it had no discernible
effect on PNT2 benign prostate cells which are known
to express FGF receptors and respond to FGF stimula-
tion [32,33]. Wang et al have previously shown that the
quantity and quality of FRS2 phosphorylation is depen-
dent on the cellular context and type of activating FGFR
[34]. Previous work from our group and that of others
have further shown that prostate cancer cells have pre-
ferential over-expression of FGFR1 and 4 while FGFR2
and 3 are unaltered or down-regulated [5,27,32,35]. We
therefore hypothesise that the observed differential
effects from knocking down FRS2 and FRS3 in malig-
nant and benign prostate cells could be due to differ-
ences in relative FGFR expression and binding to FRS2
and FRS3 and in turn, corresponding differences in the
levels of FRS2 and FRS3 phosphorylation. We acknowl-
edge that PNT2 cells are transformed using a T antigen
and may not be a perfect model to test effects in benign
cells. Further validation of these observations therefore
is needed in non transformed cells such as primary
prostate epithelial cells or cells immortalised using a dif-
ferent system (e.g. hTERT) and will be done in our
planned future work.
This differential result of FRS manipulation in benign
and malignant cells was investigated further as a thera-
peutic concept in radiation assays. Growth factor
induced MAPK activation following radiation exposure
is known to have a protective effect from cell death and
enhance cell recovery [23,24,36,37]. We tested the prin-
ciple of manipulating FRS2 and FRS3 as a mechanism of
inhibiting MAPK signalling concurrent with radiation
therapy. In these experiments we confirmed a synergistic
benefit of FRS2 and FRS3 inhibition and radiation ther-
apy. These findings are in agreement with previous stu-
dies showing that receptor tyrosine kinase inhibition
increases the sensitivity of breast cancer and glioblas-
toma cells to radiation [38-40]. Crucially, this synergistic
effect was only observed in prostate cancer cells and not
in benign cells. These results require further validation
in planned future work and with stably suppressed FRS2
and FRS3 cells and with different measurements of cell
death to test apoptosis. Nevertheless, they do suggest
the potential for using FRS2 and FRS3 as a target to
achieve selective enhancing of radio-toxicity in tumours
with relative sparing of benign tissue. Thus while FRS2
and FRS3 may not be over-expressed in cancer, they
may still conceivably be a viable target if their inhibition
is selectively effective in cancer but not benign cells.
Conclusion
In conclusion this is the first study to investigate FRS2
and FRS3 in prostate cancer. FRS2 and FRS3 exhibit
functional redundancy in prostate cancer cells and dual
inhibition effectively blocks intracellular signalling and
the mitogenic effects of multiple FGFs. We also show
that neither FRS2 nor FRS3 are apparently over-
expressed in cancer and acknowledge that this does
limit their attractiveness as a therapeutic target. Preli-
minary results of down-regulation in combination with
a cytotoxic therapy however do suggest that targeting
FRS2 and FRS3 may be specifically effective in cancer
cells. Taken together we believe that these results justify
further studies to investigate FRS2 and FRS3 in FGFR
binding and signalling in the prostate and define
mechanisms by which FRS2 and FRS3 targeting appears
to be more detrimental to cancer cells. These experi-
ments may yet show that they are valid targets to dis-
rupt global FGF signalling most likely as an adjunct to
standard cytotoxic therapies.
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